Ribomic Inc.
Ribomic Inc. scores highest on Torque (52) and lowest on Earnings (10). Its PosiPenta is 28.22 out of 100, weaker than most similar companies.
On the Penta Grid this week, Ribomic Inc. is Grid #70 of 91 in the Healthcare sector in Japan, and Grid #1,251 of 1,383 in Japan.
Compared with similar companies in the Healthcare sector in Japan.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Ribomic Inc. | 28.22 | 30 | 10 | 23 | 52 | 26 |
| SymBio Pharmaceuticals Limited | 14.10 | 0 | 43 | 2 | 6 | 20 |
| Noile-Immune Biotech Inc. | 30.82 | 36 | 12 | 9 | 55 | 41 |
| D. Western Therapeutics Institute, Inc. | 22.95 | 14 | 22 | 17 | 24 | 39 |
| Kohjin Bio Co., Ltd. | 34.55 | 54 | 39 | 9 | 36 | 36 |
| Japan Hospice Holdings Inc. | 44.69 | 72 | 68 | 5 | 32 | 47 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -2.93 |
| P/B ratio | 1.36 |
EEarnings
| Trailing EPS | ₹-13.59 |
| Forward EPS | ₹-31.72 |
NNitro
| Price | 39.88 |
| 52-week high | 72.50 |
| 52-week low | 34.44 |
| Fall from 52-week high | 45.0% |
TTorque
| Return on equity (ROE) | -42.75% |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | 0.27 |
| Market cap | ₹225 Cr |
| Insider holding | 2.89% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Ribomic Inc.'s PosiPenta score?
Ribomic Inc.'s PosiPenta is 28.22 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Where does Ribomic Inc. stand on the Penta Grid?
On the Penta Grid this week, Ribomic Inc. is Grid #70 of 91 in the Healthcare sector in Japan, and Grid #1,251 of 1,383 in Japan.
Which PosiPenta pillar is strongest for Ribomic Inc.?
Torque (durability), with a score of 52 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Ribomic Inc.?
Earnings (growth), with a score of 10 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.